Using Wegovy with an Underactive Thyroid: What the Evidence Says

Step 1: Understand what hypothyroidism does to weight, and what it does not

An underactive thyroid slows your metabolism. When your thyroid gland does not produce enough hormone, your body burns fewer calories at rest, fluid retention increases, and fatigue makes it harder to stay active. Those effects stack up on the scales. Levothyroxine replaces the missing hormone, and for many people that is enough to stabilise weight once levels normalise. For others, though, weight remains stubbornly higher even when a blood test says thyroid-stimulating hormone (TSH) is in the right range. That gap is real and recognised, it is not a willpower problem or a measurement error.

It is this group (people with well-controlled hypothyroidism who still struggle with weight) who most often ask about medicines like Wegovy. The NHS medicines information for semaglutide does not list hypothyroidism as a reason you cannot take it, which is a reasonable starting point. But a reasonable starting point is not the same as a green light; it means the question is answered case by case.

Worth knowing upfront: if your thyroid is currently undertreated or your TSH is well outside range, that is likely to be addressed before a prescriber considers adding a weight-management medicine. Stable, treated hypothyroidism is a very different situation from newly diagnosed or poorly controlled disease.

Step 2: Flag your levothyroxine, absorption timing matters more than most people realise

This is a practical step that often catches people off guard. Levothyroxine is notoriously fussy. Most people take it first thing in the morning on an empty stomach and wait 30 to 60 minutes before eating, specifically because food, coffee and certain medicines interfere with how much of the dose is absorbed. Semaglutide slows gastric emptying (the rate at which food moves through your stomach) and that same mechanism can alter how consistently oral medicines are absorbed.

There is no published evidence that Wegovy significantly disrupts levothyroxine absorption in clinical practice, but the mechanistic reason to be cautious exists, and our page on whether and how semaglutide affects thyroid function explains that relationship in more detail. Your prescriber should know you take levothyroxine, when you take it, and at what dose. In some cases, thyroid function may need monitoring more closely in the first months of starting Wegovy to check your levels stay stable. That is a conversation for your GP or thyroid specialist, not something to work out on your own. If you are the sort of person who takes your levothyroxine at 6am before the school run, it is worth telling your prescriber exactly that, the timing and the routine both matter.

The NHS England guidance on weight management injections advises that prescribers should review existing medicines as part of the assessment process, and levothyroxine sits firmly in that category.

Step 3: Know the thyroid cancer signal, what it means and what it does not

You may have read that semaglutide carries a thyroid cancer warning. Here is what the science actually says. In rodent studies, GLP-1 receptor agonists including semaglutide caused thyroid C-cell tumours at doses far above those used in humans. C-cells produce calcitonin, not thyroxine, they are a different cell type from those affected in common thyroid conditions like hypothyroidism or Hashimoto's thyroiditis. Human epidemiological data gathered since these medicines were first licensed has not confirmed the same signal in people, and NICE's appraisal of semaglutide (TA875) did not restrict its recommendation on this basis for the general population.

However, the UK licence is clear: Wegovy must not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. If that applies to you, it is an absolute contraindication. Our page on Wegovy and thyroid cancer risk goes into the evidence in detail if you want to read further, and how semaglutide affects the thyroid covers the mechanism more broadly.

Hypothyroidism and Hashimoto's are not in themselves contraindications, but they are part of your medical history that your prescriber needs to know. Do not leave them off a consultation form.

Step 4: Get the right clinical input before starting

Putting this together: if you have a well-controlled underactive thyroid and are otherwise eligible for Wegovy, there is a reasonable clinical path forward, but it runs through proper assessment, not assumption. A prescriber needs to see the full picture: your current thyroid function, your levothyroxine dose and how stable it has been, any family history of thyroid cancer, and whatever else shapes your health. It is also worth knowing that Wegovy is not currently approved for under-18s, and anyone wanting to understand the broader picture around semaglutide use in under-18s will find that covered separately. If you are pregnant or planning a pregnancy, our page on Wegovy and pregnancy sets out the current guidance before you go further.

At nume (sorry, at our clinic) every Wegovy consultation is reviewed personally by a GPhC-registered Independent Prescriber on the day it is submitted. They read your medical history, not a checklist. If your thyroid situation raises a question that needs your GP's input first, they will tell you that clearly. The service exists to get this right, not to move fast at the expense of safety. You can check your eligibility and start a free consultation whenever you are ready, and our FAQs cover common questions about the process if you want a sense of what to expect. If Wegovy is not the right fit, our weight-loss treatment overview sets out what else may be available. For anything clinical and specific to your situation, your GP or thyroid specialist remains the right first call.